TMO Thermo Fisher Scientific
High-quality biopharma toll road, but the price assumes growth and returns that organic reinvestment hasn't delivered.
The story
Thermo Fisher is the scaled toll-collector on life-science R&D and biopharma manufacturing: instruments, consumables, CDMO and CRO services, with about 80% recurring revenue and unmatched channel breadth. After the post-COVID normalization (revenue flat at about $43-45B from 2022 to 2024), organic growth has resumed in the low-to-mid single digits, and TTM revenue of $46.3B is up roughly 4%. Bolt-ons (Olink, Solventum filtration, Clario) add growth but also capital. It is a mature franchise with a durable moat, and value hinges on organic reinvestment efficiency rather than deal-driven top-line growth.
I raised Y1 growth slightly (5% to 5.5%) because TTM growth has re-accelerated and recent deals will add to it. I nudged the target margin from 23.5% to 24.5% because reported margins carry about 5 points of acquisition amortization that runs off over time, while adjusted margins of about 23% already show that level of underlying profitability (both moves are under 20% relative). Sales-to-capital stays at 1.6 for incremental organic capital; the reported 0.5 reflects legacy goodwill, not marginal economics.
Value drivers
| Revenue growth (Y1) | 5.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 12y |
| Target operating margin | 24.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.0% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 83.25B |
| PV of terminal value | 71.95B |
| Equity value | 124.28B |
| ÷ shares → per share | $336.13 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 48.88B | 5.5% | 20.6% | 9.32B | 1.59B | 7.73B | 7.10B |
| 2 | 51.48B | 5.3% | 21.6% | 10.28B | 1.62B | 8.66B | 7.29B |
| 3 | 54.13B | 5.1% | 22.6% | 11.30B | 1.65B | 9.64B | 7.46B |
| 4 | 56.81B | 5.0% | 23.5% | 12.37B | 1.68B | 10.69B | 7.59B |
| 5 | 59.52B | 4.8% | 24.5% | 13.49B | 1.69B | 11.80B | 7.68B |
| 6 | 62.25B | 4.6% | 24.5% | 14.11B | 1.71B | 12.40B | 7.41B |
| 7 | 65.00B | 4.4% | 24.5% | 14.73B | 1.72B | 13.02B | 7.14B |
| 8 | 67.75B | 4.2% | 24.5% | 15.36B | 1.72B | 13.64B | 6.87B |
| 9 | 70.49B | 4.0% | 24.5% | 15.98B | 1.71B | 14.26B | 6.59B |
| 10 | 73.21B | 3.9% | 24.5% | 16.59B | 1.70B | 14.89B | 6.32B |
| 11 | 75.91B | 3.7% | 24.5% | 17.21B | 1.68B | 15.52B | 6.04B |
| 12 | 78.56B | 3.5% | 24.5% | 17.81B | 1.66B | 16.15B | 5.77B |
Key risks
- NIH/academic funding cuts and biotech funding drought depress instrument and consumables demand
- Serial M&A at high multiples destroys value and keeps reinvestment efficiency low
- China weakness, tariffs, and pharma pricing reform (MFN) pressure biopharma capex and CDMO volumes
Catalysts
- Bioproduction and pharma-services volume recovery with onshoring-driven US manufacturing build-outs
- Margin expansion via PPI cost programs and amortization roll-off lifting GAAP margins toward adjusted levels